Patient-Reported Outcomes in Patients with Metastatic Colorectal Cancer Treated with Fruquintinib: A Prospective Observational Study

Patient-Reported Outcomes in Patients with Metastatic Colorectal Cancer Treated with Fruquintinib: A Prospective Observational Study - FRUPRO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059805

Enrollment

200

Registered

2026-03-01

Start date

2026-06-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically confirmed adenocarcinoma originating from the colon or rectum. 2.Unresectable Stage IV or recurrent colorectal cancer. 3.Age 18 years or older at the time of informed consent. 4.ECOG performance status of 0-2. 5.Planned to receive treatment with fruquintinib. 6.Able to complete PRO questionnaires.

Exclusion criteria

Exclusion criteria: 1. Deemed unsuitable for participation in the study at the discretion of the treating physician.

Design outcomes

Primary

Measure	Time frame
PRO-CTCAE	—

Secondary

Measure	Time frame
Longitudinal changes in PRO scores during the treatment period Association between treatment modifications (dose reduction, treatment interruption, or discontinuation) and deterioration in PROs Time to deterioration (TTD) of health-related quality of life (HRQoL)	—

Countries

Japan

Contacts

Public ContactHiroya Taniguchi

Aichi Cancer Center Hospital Department of Clinical Oncology

hiroya.taniguchi@aichi-cc.jp0527626111

Outcome results